Evidence map›Paper›PMID 42802866›Full record

ArticleInternational journal of nanomedicine2026

A Quercetin/Rg3-Loaded Calcium Phosphate Nanoplatform Alleviates Breast Cancer-Induced Peripheral Hyperalgesia and Enhances Antitumor Immunity.

Zhengkun Ji, Wanru Sun, Yongxin Mu, Ranran Wang, Yicun Hu, Jian Sun, Guangjun Liao, Yu Liu, Yuchi Zhao, Jinhong Yan and 2 more

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhengkun Ji *The Second School of Clinical Medicine, Shandong Medical and Pharmaceutical University, Yantai, Shandong, People's Republic of China.
Wanru Sun *Institute of Rehabilitation Medicine, School of Special Education and Rehabilitation, Shandong Medical and Pharmaceutical University, Yantai, 264003, People's Republic of China.
Yongxin Mu *The Second School of Clinical Medicine, Shandong Medical and Pharmaceutical University, Yantai, Shandong, People's Republic of China.
Ranran WangInstitute of Rehabilitation Medicine, School of Special Education and Rehabilitation, Shandong Medical and Pharmaceutical University, Yantai, 264003, People's Republic of China.
Yicun HuThe Second School of Clinical Medicine, Shandong Medical and Pharmaceutical University, Yantai, Shandong, People's Republic of China.
Jian SunDepartment of Rehabilitation Medicine, Tianjin Medical University General Hospital, Tianjin, 300000, People's Republic of China.
Guangjun LiaoDepartment of Orthopedic Surgery, Yantaishan Hospital, Yantai, 264003, People's Republic of China.
Yu LiuThe Second School of Clinical Medicine, Shandong Medical and Pharmaceutical University, Yantai, Shandong, People's Republic of China.
Yuchi ZhaoDepartment of Orthopedic Surgery, The Second Qilu Hospital of Shandong University, Jinan, 250000, People's Republic of China.
Jinhong YanDepartment of Orthopaedics, Yantai Yuhuangding Hospital, Yantai, Shandong, 264000, People's Republic of China.
Junjie JiangYantai Key Laboratory for Repair and Reconstruction of Bone and Joint, Yantaishan Hospital, Yantai, 264003, People's Republic of China.
Guofeng ZhangDepartment of Orthopedic Surgery, Yantaishan Hospital, Yantai, 264003, People's Republic of China.ORCID 0000-0003-1180-4170

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to develop a multifunctional nanoplatform, Rg3-Lip-CaPO Methods: R-LCP/Q was constructed by incorporating ginsenoside Rg3 into a lipid-coated calcium phosphate nanoplatform loaded with quercetin (Que). Its physicochemical properties, pH-responsive release, cellular uptake, antitumor activity, Ca Results: R-LCP/Q exhibited pH-responsive degradation and release of Ca Conclusion: R-LCP/Q provides preclinical proof of concept for a multifunctional nanotherapeutic strategy integrating tumor suppression, antitumor immune modulation, and cancer pain relief. The findings support further investigation of coordinated tumor-immune-nociceptive regulation as a therapeutic approach for cancer treatment.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCalcium PhosphatesGinsenosidesHyperalgesiaNanoparticlesQuercetinAnimalsApoptosisCell Line, TumorFemaleMiceMice, Inbred BALB CTissue DistributionAntineoplastic Agentscalcium phosphateCalcium PhosphatesGinsenosidesQuercetinantitumor immunitycalcium phosphate nanoparticlescancer painginsenoside Rg3immunogenic cell deathquercetinTRPV1–SP axis

Identifiers

PMID42802866
PMCPMC13616164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.